Ensysce Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on October 18, 2024, covering an event that occurred on October 17, 2024. The Company is a Delaware corporation with its principal executive offices in La Jolla, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "ENSC."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
On October 17, 2024, the Company amended its bylaws, effective November 1, 2024. The amendment reduces the number of shares required to constitute a quorum at stockholder meetings from a majority of the total votes entitled to be cast to one-third (1/3rd) of the total votes entitled to be cast.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the bylaw amendment.
Key Facts for Investor Verification
- The quorum requirement for stockholder meetings is reduced to 1/3rd of total votes entitled to be cast, effective November 1, 2024.
- The amendment was approved on October 17, 2024, and filed as Exhibit 3.2(b).
- No financial performance data or operational updates are included in this specific filing.